KODEX KODEX Bio ETF Загрузка... : Бычьи и медвежьи мнения аналитиков
Загрузка графика...
Лучшие сигналы
Лента
00:54
26 авг
26 авг
Invest directly in US biotech over Korean biotech.
The correlation between the US biotech ETF (XBI) and the Korean KODEX Bio ETF has broken since March. Instead of buying Korean biotech stocks hoping they will follow the US trend, it is better to directly invest in the US biotech ETF (XBI) which shows stronger momentum.
Выс.
11:00
23 авг
23 авг
Samsung governance names benefit from return policy.
Samsung Life and Samsung C&T are Samsung group governance-axis companies that rallied into the Samsung Electronics shareholder-return announcement, and the speaker argues they remain attractive as indirect beneficiaries of Samsung's return/group value theme. He suggests using ETFs that hold both names, such as TIGER Samsung Group ETF and KODEX Samsung Group ETF, to get exposure; Samsung Life is recovering above its 2011 moving average after a drawdown.
Сред.
02:22
20 июл
20 июл
Avoid SK Hynix leveraged ETFs.
The massive trading volume in SK Hynix single-stock leveraged ETFs (KODEX, TIGER) is fueling excessive volatility, draining liquidity from other stocks, and preventing the Samsung-SK Hynix gap from normalizing. Stopping purchases of these leveraged products alone would help stabilize the market. Moreover, if the gap widens and Hynix underperforms, these leveraged instruments will likely suffer amplified losses.
Выс.
00:52
13 июл
13 июл
Buy KODEX Bio ETF as divergence narrows.
There is an unprecedented divergence between the US XBI and the Korean Bio ETF. Expecting this gap to narrow, buying the KODEX Bio ETF is a good strategy if picking individual stocks is difficult.
Сред.
Об аналитическом покрытии KODEX
Buzzberg отслеживает KODEX (KODEX Bio ETF) в 2 источниках. Бычьих сигналов: 2, медвежьих: 0, от 3 аналитиков. Сентимент преимущественно бычий (50%). Всего отслеживаются 4 торговые идеи. За последние 7 дней: бычьих: 1, наблюдение: 1. Последние спикеры: Kim Hyeong-cheol, Choi Chang-gyu, Lee Hyuk-jin.